U.S. FDA flags Aurobindo arm’s Hyderabad plant

U.S. FDA flags Aurobindo arm's Hyderabad plant Updated – August 21, 2026 09: 04 pm IST – HYDERABAD.

What happened

Notably, the U.S. Food and Drug Administration (U.S. After a routine inspection of its facility in Sangareddy district near Hyderabad from August 17 to 21, FDA) has issued one observation to AuroPeptides, the peptide API manufacturing subsidiary of Aurobindo Pharma.

Meanwhile, the observation relates to facility and equipment maintenance and does not pertain to data integrity or related GMP compliance. Corrective action was already initiated during the course of the inspection and a formal response will be submitted within the stipulated timeline, Aurobindo Pharma remarked in a filing on Friday.

The bottom line

Taken together, the developments around U.S. FDA flags Aurobindo arm's Hyderabad plant point to a situation that is still moving, and the coming days should bring more clarity.